Sunday 18 October 2026 Export XFOR’s income statement to Excel — free account

X4 Pharmaceuticals, Inc.

In the quarter to June 2026, revenue grew 346.3%, EPS grew 96.3%, free cash flow grew 13.8% and total debt rose 1.21%, each against the same quarter a year earlier.

2.59 0.05 −1.89%

Follow XFOR

Alert me

Market cap: $261.8M
P/E: 0.0×
Fwd P/E: −5.1×
Dividend yield: —
F-score: n/a
Altman Z: −1.78
Beneish M: 8.05
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.46

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	1	1	—	2	—	1

Insider Ownership 40.59%

Capital & Financial Ratios $m

Market Cap 261.75

Revenue 15.85

Net Income (90.14)

Free Cash Flow (88.74)

Net Debt (131.21)

Current Ratio 11.30

Debt/Equity 0.49

P/E ratio 0.00

Fwd P/E (5.07)

P/S ratio 20.65

P/B ratio 2.11

Past 5Y EPS Growth —

This Y EPS Growth 65.13%

Next Y EPS Growth (7.98%)

Next Y revenue growth (54.49%)

Next 5Y EPS Growth 23.57%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 62.99%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	114	102	253	208
Receivables	1	2	1	2
Inventory	—	3	4	6
Other	—	—	—	—
	122	112	262	219

	2023	2024	2025	Q'26
Payables	9	9	6	4
ST’ Debt	—	—	—	—
Other	—	—	—	—
	23	33	26	19

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	115.68%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	20.67%	36.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	3	9	—	—	—
’25	29	2	2	3	35
’24	—	1	1	1	3
’20	3	—	—	—	3

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(20)	(21)	—	—	—
’25	(12)	(30)	(28)	(16)	(86)
’24	(34)	(30)	(34)	(33)	(131)
’23	(27)	(21)	(21)	(28)	(97)
’22	(20)	(18)	(19)	(19)	(77)
’21	(18)	(19)	(14)	(19)	(71)
’20	(16)	(11)	(14)	(18)	(59)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(20)	(26)	—	—	—
’25	(15)	(30)	(28)	(16)	(89)
’24	(34)	68	(34)	(33)	(33)
’23	(27)	(21)	(21)	(28)	(97)
’22	(20)	(19)	(19)	(19)	(77)
’21	(19)	(19)	(14)	(19)	(72)
’20	(16)	(11)	(15)	(18)	(60)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.16)	(0.13)	—	—	—
’25	0.04	(3.47)	(0.69)	(0.22)	(1.87)
’24	(7.81)	13.51	(5.41)	(6.01)	(5.71)
’23	(4.80)	(9.91)	(0.30)	(3.00)	(17.12)
’22	(21.62)	(18.02)	(7.81)	(8.71)	(45.65)
’21	(39.04)	(22.22)	(22.82)	(37.24)	(119.82)
’20	(16.82)	(22.82)	(26.13)	(27.33)	(92.79)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	1,872.00	207.00	280.80	161.40	54.00	19.50	17.16	7.83	1.35	Analyst estimates 2026–2028 Powerpack
	High	—	3,550.68	5,164.92	717.90	334.80	321.12	78.90	77.25	48.00	24.45
People
People	Employees	39	40	15	58	72	83	70	93	143	45
	Revenue/emp, $m	0.00	0.00	0.23	0.00	0.04	0.00	0.00	0.00	0.02	0.78
Income, $m
Income, $m	Revenue	—	—	4	—	3	—	—	—	3	35
	Gross margin, %	—	—	100.00	—	100.00	—	—	—	68.83	83.60
	EBT	(23)	(22)	(33)	(53)	(62)	(89)	(94)	(101)	(37)	(79)
	EBT margin, %	0.00	0.00	(951.00)	0.00	(2,066.10)	0.00	0.00	0.00	(1,452.48)	(225.44)
	Net income	(23)	(22)	(33)	(53)	(62)	(89)	(94)	(101)	(37)	(79)
	Depreciation	0	0	0	0	0	10	1	0	1	1
Per share, $
Per share, $	Revenue	0.00	0.00	228.76	0.00	4.49	0.00	0.00	0.00	0.38	0.83
	Earnings	(8,059.58)	(1,442.10)	(2,177.67)	(139.04)	(92.79)	(119.82)	(45.65)	(17.12)	(5.71)	(1.87)
	Cash flow	(7,461.72)	(1,392.88)	(1,661.44)	(125.18)	(87.97)	(82.70)	(36.45)	(16.28)	(19.53)	(2.02)
	Capex	(25.17)	(24.71)	(2.22)	2.15	(2.04)	(0.72)	(0.05)	(0.01)	14.57	(0.07)
	Free cash flow	(7,486.90)	(1,417.58)	(1,663.66)	(123.02)	(90.01)	(83.41)	(36.50)	(16.29)	(4.96)	(2.10)
	Book value	(5,766.90)	3,837.06	(811.18)	336.60	108.88	75.12	35.01	8.62	3.30	4.40
	Shares, m	0	0	0	0	1	1	2	6	7	42
Valuation, ×
Valuation, ×	P/E	—	—	0.00	—	0.00	—	—	—	0.00	0.00
	P/S	—	—	0.00	—	0.00	—	—	—	26.56	4.82
	P/B	—	—	0.00	—	1.77	—	—	—	6.66	0.91
	EV/Sales	—	—	0.00	—	0.00	—	—	—	21.90	(0.19)
	EV/FCF	—	—	(0.32)	—	(1.40)	—	—	—	(4.64)	(0.42)
Cash, $m
Cash, $m	Operating cash flow	(22)	(21)	(25)	(48)	(59)	(71)	(77)	(97)	(131)	(86)
	Capex	0	0	0	1	(1)	(1)	0	0	98	(3)
	Free cash flow	(22)	(22)	(25)	(47)	(60)	(72)	(77)	(97)	(33)	(89)
Balance, $m
Balance, $m	Working capital	(6)	69	1	120	71	74	106	99	79	236
	Total debt	10	10	10	21	33	34	34	55	75	76
	Net debt	7	(67)	2	(105)	(46)	(48)	(88)	(60)	(27)	(177)
	Shareholders’ equity	(17)	59	(12)	129	73	64	74	51	22	186
Returns, %
Returns, %	ROA	(268.79)	(56.26)	(79.62)	(62.59)	(43.82)	(85.52)	(70.69)	(66.81)	(25.50)	(36.25)
	ROIC	0.00	0.00	0.00	(134.47)	(137.23)	(321.23)	0.00	0.00	0.00	(566.65)
	ROE	50.61	(2,330.44)	395.09	(204.85)	(61.51)	(149.61)	(139.26)	(161.67)	(102.26)	(75.99)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
EYPT EyePoint, Inc.	$270.7M	— (loss-making)	— (loss-making)	−90.49% (below 0%: shrinking)	n/m	+0.41% (above 0%: growing)	100.00%	(19,207.10%)	Compare
PALI Palisade Bio, Inc.	$268.4M	2.2×	— (loss-making)	+19,900.00% (above 0%: growing)	n/m	−318.44% (below 0%: shrinking)	100.00%	(2,339.60%)	Compare
ABEO Abeona Therapeutics Inc.	$265.9M	— (loss-making)	— (loss-making)	+225.14% (above 0%: growing)	n/m	+17.11% (above 0%: growing)	63.30%	(119.97%)	Compare
PRLD Prelude Therapeutics Incorporated	$265.0M	— (loss-making)	— (loss-making)	+42.60% (above 0%: growing)	n/m	+40.32% (above 0%: growing)	100.00%	(270.93%)	Compare
CABA Cabaletta Bio, Inc.	$262.8M	— (loss-making)	—	—	n/m	−35.72% (below 0%: shrinking)	0.00%	0.00%	Compare
XFOR X4 Pharmaceuticals, Inc.	$261.8M	— (loss-making)	— (loss-making)	+346.33% (above 0%: growing)	n/m	+13.76% (above 0%: growing)	81.64%	(186.13%)
RCKT Rocket Pharmaceuticals, Inc.	$259.1M	— (loss-making)	—	—	n/m	+19.16% (above 0%: growing)	0.00%	0.00%	Compare
VNDA Vanda Pharmaceuticals Inc.	$256.4M	— (loss-making)	— (loss-making)	−3.92% (below 0%: shrinking)	n/m	−101.02% (below 0%: shrinking)	92.95%	(126.28%)	Compare
IKT Inhibikase Therapeutics, Inc.	$255.4M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−123.23% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$263.9M	—	—	+19.34%	—	−17.65%	78.13%	(123.12%)

All 614 Biotechnology stocks →

X4 Pharmaceuticals, Inc. (XFOR) key facts

X4 Pharmaceuticals, Inc. (XFOR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, XFOR traded at $2.59, a market capitalization of $261.8 million.
Return on equity was −76.0% and debt-to-equity 0.49.
Its Altman Z-score is −1.78 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.